Ticker: COCP

Cocrystal Pharma, Inc. (NASDAQ: COCP) Short take: management cut operating spend and advanced clinical work (CDI‑988 Phase 1; CC‑42344 Phase 2a), but cash burn remains material and auditors/management flag a going‑concern-additional financing is required within 12 months. Key facts and figures (a...

Cocrystal Pharma, Inc. (NASDAQ: COCP) is currently navigating challenging financial conditions as it progresses in the biopharmaceutical sector, specifically in developing antiviral drug candidates. The company’s recent income statement for Q1 2025 reveals both positive movements and ongoing stru...